Alopecia areata in atopic dermatitis: coincidence or regularity?
DOI: 10.32364/2587-6821-2022-6-2-85-91
S.Yu. Petrova1, V.I. Albanova2
1І.І. Mechnikov Research Institute of Vaccines and Sera, Moscow, Russian Federation
2M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow,
Russian Federation
Extensive trials have identified a close relationship between atopic dermatitis (AD) and alopecia areata (AA). This review paper summarizes and analyzes available data on the immunological pattern of AD-associated AA. The analysis of scientific findings suggests that epidermal barrier dysfunction in AD promotes AA in the presence of target genes contributing to its development. Both pathological entities negatively affect each other. The results are the reduction in regulatory T cell (Treg) suppression activity and an increase in inflammatory and autoimmune activity of Th-17 cells. Hyperergic Th2 response affects AD-associated AA clinical presentations. The regression of bald patches after IL-4, IL-13, and histamine receptors blockage further establishes the association between AA and AD. The possibility of atopic alopecia requires both skin and hair care products in AD. Dry peeling skin vulnerable to infections should be treated to reduce the risk of autoimmunity in AA. The presence of two family lines of genetic predisposition (atopy and AA) results in severe combined manifestations of these disorders in progeny. Therefore, attention should be paid to early AD signs in children in these families to commence treatment timely.
Keywords: atopic dermatitis, аlopecia areata, genetics, autoimmunity, epidermal barrier, regulatory T cells, immune privilege, hair follicle, T helper 17 cells, mast cells.
For citation: Petrova S.Yu., Albanova V.I. Alopecia areata in atopic dermatitis: coincidence or regularity? Russian Medical Inquiry. 2022;6(2):85–91 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-85-91.
About the authors:
Stanislava Yu. Petrova — C. Sc. (Med.), senior researcher of the Laboratory of Allergen Development, І.І. Mechnikov Research Institute of Vaccines and Sera; 5A, Malyy Kazennyy lane, Moscow, 105064, Russian Federation; ORCID iD 0000-0003-3034-0148.
Vera I. Albanova — Dr. Sc. (Med.), Professor, associate professor of the Department of Dermatovenerology and Dermatooncology of the Faculty of Advanced Medical Treatment, M.F. Vladimirskiy Moscow Regional Research and Clinical Institute; 61/2, Shchepkin str., Moscow, 129110, Russian Federation; ORCID iD 0000-0001-8688-7578.
Contact information: Stanislava Yu. Petrova, e-mail: petrovastanislava@yandex.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 25.11.2021.
Revised 20.12.2021.
Accepted 12.01.2022.
2. Albanova V.I., Pampura A.N. Atopic dermatitis. 2nd ed. M.: GEOTAR-Media; 2020 (in Russ.). DOI: 10.33029/9704-5640-8-АТП-2020-1-144.
3. Brunner P.M., Guttman-Yassky E., Leung D.Y. The immune ology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(45):65–76. DOI: 10.1016/j.jaci.2017.01.011.
4. Akdis C.A., Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin Exp Allergy. 2003;33(12):1618–1621. DOI: 10.1111/j.1365-2222.2003.01803.x.
5. Alopecia areata. Clinical recommendations. 2016 (in Russ.).
6. Serbina I.M. Cytokine-mediated mechanisms of development of alopecia areata. Belgorod State University Bulletin. Medicine. Pharmacy. 2014;24(195):50–54 (in Russ.).
7. Guo H., Cheng Y., Shapiro J., McElwee K. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335–1351. DOI: 10.1586/1744666X.2015.1085306.
8. Mohan G.C., Silverberg J.I. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2015;151(5):522–528. DOI: 10.1001/jamadermatol.2014.3324.
9. Ivert L.U., Wahlgren C.-F., Lindelöf B. et al. Association between atopic dermatitis and autoimmune diseases: a population‐based case-control study. Br J Dermatol. 2021;185(2):335–342. DOI: 10.1111/bjd.19624.
10. Barahmani N., Schabath M.B., Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61(4):581–591. DOI: 10.1016/j.jaad.2009.04.031.
11. Goh C., Finkel M., Christos P.J., Sinha A.A. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune diseases and positive family history. J Eur Acad Dermatol Venereol. 2006;20(9):1055–1060. DOI: 10.1111/j.1468-3083.2006.01676.x.
12. Kageyama R., Ito T., Hanai S. et al. Immunological properties of atopic. Immunological properties of atopic dermatitis-associated alopecia areata. Int J Mol Sci. 2021;22(5):2618. DOI: 10.3390/ijms22052618.
13. Melnichenko N.E., Kovaleva V.V., Aristova E.Yu. Hair diseases: textbook. Blagoveshchensk; 2014 (in Russ.).
14. Barilo A.A., Smirnova S.V., Olyanina I.M. Clinical case of focal alopecia in a child with atopy. Meditsinskaya Immunologiya. 2021;23(1):191–196 (in Russ.). DOI: 10.15789/1563-0625-CC0-2074.
15. Pratt C.H., King L.E., Messenger A.G. et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. DOI: 10.1038/nrdp.2017.11.
16. Spano F., Donovan J.C. Alopecia areata: part 1: pathogenesis, diagnosis, and prognosis. Can Fam Physician. 2015;61(9):751–755. PMID: 26371097.
17. McElwee K.J., Gilhar A., Tobin D.J. et al. What causes alopecia areata? Exp Dermatol. 2013;22(9):609–626. DOI: 10.1111/exd.12209.
18. Strazzulla L.C., Wang E.H.C., Avila L. et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. DOI: 10.1016/j.jaad.2017.04.1141.
19. Rerknimitr P., Otsuka A., Nakashima C., Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:1–14. DOI: 10.1186/s41232-017-0044-7.
20. Kono M., Nomura T., Ohguchi Y. et al. Comprehensive screening for a complete set of japanese-population-specific filaggrin gene mutations. Allergy. 2014;69(4):537–540. DOI: 10.1111/all.12369.
21. Margolis D.J., Apter A.J., Gupta J. et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012;130(4):912–917. DOI: 10.1016/j.jaci.2012.07.008.
22. Sroka-Tomaszewska J., Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22(8):4130. DOI: 10.3390/ijms22084130.
23. Kezic S., O’Regan G.M., Lutter R. et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol. 2012;129:1031–1039. DOI: 10.1016/j.jaci.2011.12.989.
24. Betz R., Petukhova L., Ripke S. et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nature. 2015;466:113–117. DOI: 10.1038/ncomms6966.
25. Hamed F.N., Åstrand А., Bertolini М. et al. Alopecia areata patients show deficiency of FOXP3+CD39+ T regulatory cells and clonotypic restriction of Treg TCRβ-chain, which highlights the immunopathological aspect of the disease. PLoS One. 2019;14(7):e0210308. DOI: 10.1371/journal.pone.0210308.
26. Betz R.C., Pforr J., Flaquer A. et al. Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease. J Invest Dermatol. 2007;127:2539–2543. DOI: 10.1038/sj.jid.5700915.
27. Moskalets O.V. Role of infections in autoimmune disease development. Kazan medical journal. 2017;98(4):586–591 (in Russ.). DOI: 10.17750/KMJ2017-586.
28. Samoilikov P.V., Gervazieva V.B., Kozhevnikov S.A. IgE and IgG autoreactivity in children with atopic dermatitis. Ros Vestn Perinatol Pediat. 2012;57(1):97–103 (in Russ.).
29. Varlamov E.E., Pampura A.N., Sukhorukov V.S. The importance of cytokines for the atopic dermatitis pathogenesis. Ros Vestn Perinatol Pediat. 2018;63(1):28–33 (in Russ.). DOI: 10.21508/1027-4065-2018-63-1-28-33.
30. Zeller S., Rhyner C., Meyer N. et al. Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. J Allergy Clin Immunol. 2009;124(2):278–285. DOI: 10.1016/j.jaci.2009.05.015.
31. Speiser J.J., Mondo D., Mehta V. et al. Regulatory T-cells in alopecia areata. J Cutan Pathol. 2019;46(9):653–658. DOI: 10.1111/cup.13479.
32. Ito T., Ito N., Saatoff M. et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol. 2008;128(5):1196–1206. DOI: 10.1038/sj.jid.5701183.
33. Simonetti O., Lucarini G., Bernardini M.L. et al. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol. 2004;150(5):940–948. DOI: 10.1111/j.1365-2133.2004.05881.x.
34. Yarilin A.A. Immunologiya. M.: GEOTAR-Media; 2010 (in Russ.).
35. Tikhonovskaya I.V., Lesnichaya O.V. Pathomorphological manifestations of alopecia areata. Vestnik VGMU. 2017;16(1):80–87 (in Russ.). DOI: 10.22263/2312-4156.2017.1.80.
36. Gilhar A., Kalish R.S. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64–69. DOI: 10.1016/j.autrev.2005.07.001.
37. Zhulaj G.A., Oleinik E.K. CD4+CD25+FOXP3+ regulatory T-lymphocyte. Prospective applications in immunotherapy. Transactions of the Karelian Research Centre of the Russian Academy of Sciences. 2012;2:3–17 (in Russ.).
38. Sviridova V.S., Klimov V.V., Denisov A.A. et al. Immunoregulator subpopulations of T-cells in tumor growth and allergic diseases. Siberian Journal of Oncology. 2010;3(39):38–47 (in Russ.).
39. Wang A.X., Xu Landén N. New insights into T cells and their signature cytokines in atopic dermatitis. IUBMB Life. 2015;67(8):601–610. DOI: 10.1002/iub.1405.
40. Tan Q., Yang H., Liu E.M., Wang H. Establishing a role for interleukin-17 in atopic dermatitis-related skin inflammation. J Cutan Med Surg. 2017;21(4):308–315. DOI: 10.1177/1203475417697651.
41. Kuwabara Т., Ishikawa F., Kondo M., Kakiuchi T. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017;2017:3908061. DOI: 10.1155/2017/3908061.
42. Siebenhaar F., Sharov A.A., Peters E.M. et al. Substance P as an immunomodulatory neuropeptide in a mouse model for autoimmune hair loss (alopecia areata). J Invest Dermatol. 2007;127(6):1489–1497. DOI: 10.1038/sj.jid.5700704.
43. Di Bari F. Atopic dermatitis and alpha-chemokines. Clin Ter. 2015;166(3):182–187. DOI: 10.7417/CT.2015.1852.
44. Hendricks A., Yosipovitch G., Shi V. Dupilumab use in dermatologic conditions beyond atopic dermatitis — a systemic review. J Dermatol Treat. 2021;32(1):19–28. DOI: 10.1080/09546634.2019.1689227.
45. Pourang A., Mesinkovska N.A. New and emerging therapies for alopecia areata. Drugs. 2020;80(7):635–646. DOI: 10.1007/s40265-020-01293-0.
46. Lee S., Kim B.J., Lee Y.B., Lee W.S. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145–1151. DOI: 10.1001/jamadermatol.2018.2312.
47. Gong Y., Zhao Y., Zhang X. et al. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata. Exp Dermatol. 2020;29:231–238. DOI: 10.1111/exd.13758.
48. Yoshino T., Asada H., Ando Y. et al. Impaired responses of peripheral blood mononuclear cells to T-cell stimulants in alopecia areata patients with a poor response to topical immunotherapy. Br J Dermatol. 2001;145(3):415–421. DOI: 10.1046/j.1365-2133.2001.04398.x.
49. Yoshizawa Y., Kawana S. Efficacy of ebasitne in the treatment of alopecia areata. Jpn J Dermatol. 2005;115:1473–1480. DOI: 10.1016/s0190-9622(98)70048-9.
50. Bertolini M., Zilio F., Rossi A. et al. Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS ONE. 2014;9(5):e94260. DOI: 10.1371/journal.pone.0094260.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать